- Home
- CGEN vs INO Comparison
CGEN vs INO Comparison
Compare CGEN & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEN | INO |
|---|---|---|
| Founded | 1993 | 1979 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 116.1M |
| IPO Year | 2000 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CGEN | INO |
|---|---|---|
| Price | $1.98 | $1.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $9.00 |
| AVG Volume (30 Days) | 538.0K | ★ 2.3M |
| Earning Date | 03-03-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,903,000.00 | $182,337.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $231.15 | $21,214.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $1.30 |
| 52 Week High | $2.66 | $2.98 |
Technical Indicators
Market Signals| Indicator | CGEN | INO |
|---|---|---|
| Relative Strength Index (RSI) | 71.41 | 39.67 |
| Support Level | $1.43 | $1.50 |
| Resistance Level | $2.01 | $1.72 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 94.83 | 17.71 |
Price Performance
Historical ComparisonAbout CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.